The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
Open Access
- 12 June 2021
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 27 (5) , 802-813
Abstract
Introduction: Inhibitors develop less frequently in haemophilia B (HB) than haemophilia A (HA). However, when present, the success of tolerization by immune tolerance induction (ITI) therapy is lower and the risk of complications higher.Aim: To evaluate the use and outcome of ITI in patients with HB and inhibitors.Methods: Subjects include singletons or siblings with a current/history of inhibitors enrolled in B‐Natural—an observational study designed to increase understanding of clinical management of patients with HB. Patients were followed for 6 months and information on demographics, medical and social history, and treatment were recorded.Results: Twenty‐nine patients with severe HB and inhibitors were enrolled in 24 centres. Twenty‐two underwent one or more courses of ITI with or without immune suppression. Eight patients (36.4%) were successfully tolerized after the first course of ITI. One of these successes (12.5%) experienced allergic manifestations, whereas the corresponding number for the 10 treatment failures was five (50%). One of seven (14.2%) patients with large deletions and three of eight (37.5%) with nonsense mutations were tolerized at the first attempt, and all patients experiencing nephrosis either failed or were on‐going. At study end, 11 (50%) were considered successfully tolerized after one or more ITI courses, three were unsuccessful, and eight were still undergoing treatment.Conclusion: Our data underscore the possibilities and difficulties of achieving tolerization in patients with HB with inhibitors. The type of mutation and complications appear to correlate with ITI outcome, but more accurate definitions of successful ITI are warranted.Keywords
This publication has 25 references indexed in Scilit:
- Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patientPediatric Nephrology, 2013
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- Inhibitors in factor IX deficiency a report of the ISTH‐SSC international FIX inhibitor registry (1997–2006)Haemophilia, 2009
- The North American Immune Tolerance Registry: contributions to the thirty‐year experience with immune tolerance therapyHaemophilia, 2009
- Immune tolerance induction with mycophenolate‐mofetil in two children with haemophilia B and inhibitorHaemophilia, 2007
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007
- Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitorsHaemophilia, 2006
- Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitorsHaemophilia, 2006
- Tolerance induction using the Malmö treatment model 1982–1995Haemophilia, 1999
- MEASUREMENT OF ANTI-FACTOR IX IGG SUBCLASSES IN HAEMOPHILIA B PATIENTS WHO DEVELOPED INHIBITORS WITH EPISODES OF ALLERGIC REACTIONS TO FACTOR IX CONCENTRATESThrombosis Research, 1996